The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Stifel raised the firm’s price target on Alnylam (ALNY) to $345 from $300 and keeps a Buy rating on the shares following the recent FDA ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark ...

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its ...

Alnylam Pharmaceuticals (ALNY) shares soared 11.8% in the last trading session to close at $283.34. The move was backed by solid volume with far more shares changing hands than in a normal session.

Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major ...